With CMTA support of $141,000, researchers led by Gabriel Corfas, PhD, at the Kresge Hearing Research Institute at Michigan Medicine are conducting a two-year study to examine hearing and balance as potential biomarkers and clinical trial outcome measures in CMT1A.
Hearing and balance rely on precise signaling between the inner ear, the peripheral nerves, and the brain. Balance difficulties are common in CMT, yet they are not well captured by many existing outcome measures. This project focuses on whether changes in this signaling can provide data relevant to clinical trial measurement to show if a potential treatment is working.
Corfas and his team will use surveys and clinical assessments in people living with CMT1A, with results compared to those from individuals without. The goal of this work is to determine whether these assessments are suitable for further development as outcome measures in future CMT1A clinical trials.
